Stacey Simms에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Stacey Simms 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
Player FM -팟 캐스트 앱
Player FM 앱으로 오프라인으로 전환하세요!
Player FM 앱으로 오프라인으로 전환하세요!
Diabetes Connections | Type 1 Diabetes
모두 재생(하지 않음)으로 표시
Manage series 2391891
Stacey Simms에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Stacey Simms 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
The T1D news show you've been waiting for! Long-time broadcaster, blogger and diabetes mom Stacey Simms interviews prominent advocates, authors and speakers. Stacey asks hard questions of healthcare companies and tech developers and brings on "everyday' people living with type 1. Great for parents of T1D kids, adults with type 1 and anyone who loves a person with diabetes.
…
continue reading
695 에피소드
모두 재생(하지 않음)으로 표시
Manage series 2391891
Stacey Simms에서 제공하는 콘텐츠입니다. 에피소드, 그래픽, 팟캐스트 설명을 포함한 모든 팟캐스트 콘텐츠는 Stacey Simms 또는 해당 팟캐스트 플랫폼 파트너가 직접 업로드하고 제공합니다. 누군가가 귀하의 허락 없이 귀하의 저작물을 사용하고 있다고 생각되는 경우 여기에 설명된 절차를 따르실 수 있습니다 https://ko.player.fm/legal.
The T1D news show you've been waiting for! Long-time broadcaster, blogger and diabetes mom Stacey Simms interviews prominent advocates, authors and speakers. Stacey asks hard questions of healthcare companies and tech developers and brings on "everyday' people living with type 1. Great for parents of T1D kids, adults with type 1 and anyone who loves a person with diabetes.
…
continue reading
695 에피소드
All episodes
×D
Diabetes Connections | Type 1 Diabetes
1 What does “Smart MDI” really mean? A deep dive into Medtronic’s new InPen™ app 31:35
31:35
나중에 재생
나중에 재생
리스트
좋아요
좋아요
31:35We're taking a deep dive into Medtronic’s InPen with missed meal dose detection. This was approved just a few weeks ago and paves the way for the launch of what they’re calling Smart MDI. I’m taking to Madison Smith, Therapy Chief Engineer for MDI Systems at Medtronic Diabetes. She’ll explain what’s new here, how it all works and what she – as someone who lives with type 1 – would love to see next . This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.…
D
Diabetes Connections | Type 1 Diabetes
1 In the News... BIG beta cell transplant news, a new pump team-up, FDA moves on GLP-1 compounds, and more! 6:15
6:15
나중에 재생
나중에 재생
리스트
좋아요
좋아요
6:15It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Sana announces beta cell transplantation without the need for immunosuppresion drugs, Modular Medical teams up with Nudge BG for a brand new completely closed-loop system, the FDA moves forward to crack down on compounded Ozempic and Mounjaro, Dexcom and Abbott bury the legal hatchett for a while, and more. Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Big news from Sana Biotechnology. Their first in human study of islet cells without any immunosuppression appears to be a success. This is very early and hasn’t yet been peer reviewed and published.. but after four weeks, there were no safety issues and the transplanted beta cells were producing insulin. Sana’s CEO says “As far as we are aware, this is the first study showing survival of an allogeneic transplant with no immunosuppression or immune-protective device in a fully immune competent individual. Safe cell transplantation without immunosuppression has the potential to transform the treatment of type 1 diabetes and a number of other diseases.” I’ve reached out to Sana to get more on this.. love to talk to them soon. https://www.bakersfield.com/ap/news/sana-biotechnology-announces-positive-clinical-results-from-type-1-diabetes-study-of-islet-cell/article_d0390fd6-99cb-53bd-b04d-9337121e01bf.html XX FDA says no for sotagliflozin as an adjunct to insulin therapy for glycemic control in adults with type 1 diabetes (T1D) and chronic kidney disease (CKD). Studies showed a meaningful reduction in A1C but a meaningful increase in DKA. The FDA first rejected this in 2019 and was resubmitted last summer. But The advisory committee voted 11 to 3 against the approval of sotagliflozin stating that the benefits of sotagliflozin do not outweight the risks in adults with T1D and CKD. Sotagliflozin is currently approved under the brand name Inpefa to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with 1) heart failure; or 2) type 2 diabetes mellitus, CKD, and other cardiovascular risk factors. According to Lexicon, Inpefa will continue to be manufactured and made available to patients. https://www.renalandurologynews.com/news/fda-denies-approval-of-zynquista-for-type-1-diabetes-and-ckd/ XX Two companies we’ve been following are teaming up.. Modular Medical has an FDA clear patch pump and Nudge BG has an adaptive full closed loop. They’ve announced a new partnership agreement. From the release: Modular Medical's easy-to-use and cost-effective MODD1 insulin pump technology. Our combined system is intended to nudge blood glucose by making small changes to insulin delivery based on estimated glucose inputs from a continuous glucose monitor." Familiar name to some of you, Lane Desborough is the founder of Nudge BG. He says this will be a fully automated system, no mealtime bolusing needed. https://www.accesswire.com/957703/modular-medical-announces-licensing-and-partnership-agreement-with-nudge-bg XX Beta Bionics filed for an initial public offering on Monday. The company did not disclose the number of shares it will offer or the price range. Beta Bionics plans for shares to be listed on the Nasdaq under the ticker symbol “BBNX.” The Irvine, California-based company makes an insulin pump called the iLet Bionic Pancreas, which was cleared by the Food and Drug Administration in 2023. Beta Bionics plans to use the proceeds to grow its sales and manufacturing infrastructure and develop new features for its device. https://www.medtechdive.com/news/beta-bionics-insulin-pump-files-ipo/736805/ XX Tandem Diabetes Care, Inc. signed a multi-year collaboration agreement with the University of Virginia Center for Diabetes Technology (UVA) to advance research and development efforts on fully automated closed-loop insulin delivery systems. There’s a long history here – UVA is where the Control IQ algorithm was developed. This agreement seems to keep the team together for another decade. https://www.businesswire.com/news/home/20250107162995/en/Tandem-Diabetes-Care-Enters-Multi-Year-Research-Collaboration-with-UVA-Center-for-Diabetes-Technology-for-Development-of-Advanced-Insulin-Delivery-Systems XX New study says insulin is still the best treatment for gestational diabetes, compared to oral glucose-lowering medications. Metformin and gluburide are being closely looked at since they're easier to administer, less costly, and have better acceptance among patients. But this study says insulin was a bit better – slight more babies were born larger for the metformin group, and more moms had hypoglycemia. https://www.medpagetoday.com/obgyn/pregnancy/113651 XX In its Citizen Petition to the FDA, Novo Nordisk argued that there is no clinical need to allow compounding for liraglutide, the type 2 diabetes injection it sells as Victoza. Novo Nordisk last month filed a Citizen Petition with the FDA asking the federal agency to exclude its type 2 diabetes injection Victoza (liraglutide) from a proposed list of drugs eligible for compounding. https://www.biospace.com/fda/novo-launches-citizen-petition-to-block-compounded-victoza XX Bit of an update on compounded terzepatide and semaglutide. The FDA is allowing a grace period of 60 days before starting to enforce the end of allowing compounds of Mounjaro. Meanwhile, semaglutide remains on the FDA’s shortage list for several dose strengths, though all doses have been reported as “available” since late October 2024. Compounding pharmacies, especially larger 503B “outsourcing facilities,” maintain they provide an essential public service by offering lower-cost versions of medications that can cost over $1,000 per month. Many insurers still refuse to cover brand-name GLP-1 products for weight loss. Yet the FDA has reported hundreds of adverse event reports allegedly linked to compounded versions of these drugs, which do not undergo the same rigorous manufacturing inspections and clinical testing as approved brands. https://www.drugdiscoverytrends.com/compounders-and-drugmakers-clash-over-compounded-weight-loss-drugs-with-fda-in-the-middle/ XX Interesting story here.. this study says a fecal transplant can help people with type 1 and severe gastroenteropathy. The researchers say diabetic gastroenteropathy commonly affects individuals with type 1 diabetes, causing debilitating symptoms like nausea, vomiting, bloating, and diarrhea; however, treatment options remain limited. Researchers conducted a novel clinical trial to test the benefits of FMT in adult patients with type 1 diabetes and severe symptoms of gastroenteropathy, who were randomly assigned to receive either FMT or placebo capsules as the first intervention. After four weeks, Compared with placebo, FMT led to significant changes in the diversity of the gut microbiome. https://www.medscape.com/viewarticle/fmt-shows-early-success-type-1-diabetes-bowel-issues-2025a10000bg XX A couple of weeks ago, listeners told me that the Dexcom geofencing issue we reported on seems to be resolved. Dexcom is now confirming this. Previously, if you had an issue with Dexcom G7 outside of your home country, you couldn’t reinstall or use the app without customer support. As of last month, the geofencing issue has now been resolved with the latest Dexcom G7 2.6 app update. Can I travel with my Dexcom G7? | Dexcom XX Abbott and Dexcom settled all patent lawsuits related to continuous glucose monitors (CGMs). The two competitors, who lead the U.S. market for CGMs, agreed on Dec. 20 to resolve all outstanding patent disputes and not sue each other over patents for 10 years. Dexcom and Abbott previously reached a settlement in 2014 related to their diabetes devices, which included a cross-licensing deal and an agreement not to sue each other until 2021. After that agreement expired, the companies filed a volley of patent lawsuits. https://www.medtechdive.com/news/abbott-dexcom-settle-cgm-patent-lawsuits/736300/…
D
Diabetes Connections | Type 1 Diabetes
1 T1D Tech Trends: VIVI Smart and what we’re watching at the Consumer Electronics Show 26:45
26:45
나중에 재생
나중에 재생
리스트
좋아요
좋아요
26:45Every January the Consumer Electronics Show gives us a glimpse at what technology might be coming. This show used to be full of phones and TV screens, but more and more CES is featuring health care. We’re taking a deep dive into one of the innovations on display - VIVI Smart - which aims to make multiple daily injections easier. Plus, other diabetes tech from the show that we think we’ll actually be using.. and some that may be more wishful thinking. My guest this week is Ron Nagar, the founder and CEO of TempraMed, the company that makes the VIVI Cap. I’ve talked about this product before, and we’ve used it with success.. Ron will talk about what’s new here. I think this is a great and really interesting trend to make MDI easier and more automated. Most people around the world do not use insulin pumps and while I’m grateful for the automation of the AID systems – it’s really important that companies continue to serve the entire diabetes population. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Disclosure: Tempramed has donated a VIVI Cap for our Moms' Night Out and is an affiliate sponsor of the podcast. Join us at an upcoming Moms' Night Out event! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.…
D
Diabetes Connections | Type 1 Diabetes
1 What’s next for type 1 diabetes? A look ahead to 2025 with Dr. David Ahn 50:19
50:19
나중에 재생
나중에 재생
리스트
좋아요
좋아요
50:19This week, a look ahead to 2025! What will the new year bring for diabetes technology, research, and practical stuff that we’ll actually use? A fun conversation about the next twelve months with endocrinologist Dr. David Ahn. He's Chief of Diabetes at the Mary and Dick Allen Diabetes Center for Hoag Hospital and shares tech reviews and other options on social media her e This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.…
D
Diabetes Connections | Type 1 Diabetes
1 The Top Ten T1D Stories of the Year: A look back at our 2024 episodes 13:44
13:44
나중에 재생
나중에 재생
리스트
좋아요
좋아요
13:44It's a special end of the year episode of Diabetes Connections! We produced more than 70 podcast episodes this year. In my mind, these are the top ten biggest T1D stories we covered. What do YOU think is the top story? What did I miss? Let me know in the FB group or email me! This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.…
D
Diabetes Connections | Type 1 Diabetes
1 In the News... Inhaled Insulin Studied for Kids, Dexcom Launches AI, App for Driving & T1D, and more! 6:25
6:25
나중에 재생
나중에 재생
리스트
좋아요
좋아요
6:25It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: Mannkind releases info about it's Afrezza pediatric studies, Dexcom launches AI tech with Stelo, Health Canada approves Tandem/Dexcom G7, diabetes drug may help sleep apnea, an app in development to help drivers with T1D and more! Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Mannkid expects to talk to the FDA about Afrezza inhaled insulin for pediatric approval early in 2025. The company just announced six-month results from its Phase 3 INHALE-1 study of kids aged 4-17 with type 1 or type 2 diabetes comparing either inhaled pre-meal insulin or multiple daily injections (MDI) of rapid-acting insulin analog, both in combination with basal insulin. A 26-week extension phase in which all remaining MDI patients were switched to inhaled insulin is ongoing. HbA1c change over 26 weeks exceeded the prespecified non-inferiority margin of 0.4% (0.435%), largely driven by the variability of a single patient who did not adhere to the study protocol. A modified ITT (mITT) analysis, which excluded this subject, did not exceed the predetermined threshold of 0.4% (0.370%), thereby establishing the non-inferiority of Afrezza to MDI, which was the primary endpoint of the study. Over 26 weeks of treatment, there were no differences in lung function parameters between the treatment groups, There were no differences between groups or concerns in other safety measures, including hypoglycemia. https://www.medscape.com/viewarticle/inhaled-insulin-benefits-kids-diabetes-too-2024a1000nex XX Dexcom announces the use of AI for its Stelo platform. The company says the new Dexcom GenAI platform will analyze individual health data patterns to reveal a direct association between lifestyle choices and glucose levels while providing actionable insights to help improve metabolic health. Stelo users will start seeing the features this week. The AI is modeled after Google Cloud’s Vertex AI and Gemini models. We’ll hear more about this in January – Dexcom will be part of a panel at the Consumer Electronics Show about AI and healthcare. BTW this press release is the first time I’ve seen what seems to be a new slogan for Dexcom – Discover What You’re Made Of. https://www.businesswire.com/news/home/20241217011997/en/Dexcom-Launches-the-First-Generative-AI-Platform-in-Glucose-Biosensing XX Staying with Dexcom, users report that the geofencing issue we reported on seems to be resolved. Previously, if you had an issue with Dexcom G7 outside of your home country, you couldn’t reinstall or use the app without customer support. With the latest iOS and Android G7 apps, this seems to be resolved. This is according to the folks in the DIY community who first brought it to my attention. XX Interesting insulin development to watch. Egypt approves EVA Pharma's insulin drug products, which is a collbaration between Eli llly and EVA, an Egyptian company. The Egyptian Drug Authority approved the insulin glargine injection manufactured by EVA Pharma through a collaboration with Eli Lilly and Company (NYSE: LLY). Launched in 2022, the collaboration aims to deliver a sustainable supply of high-quality, affordable human and analog insulin to at least one million people annually living with type 1 and type 2 diabetes in low- to middle-income countries (LMICs), most of which are in Africa. Lilly has been supplying its active pharmaceutical ingredient (API) for insulin to EVA Pharma at a significantly reduced price and providing pro-bono technology transfer to enable EVA Pharma to formulate, fill and finish insulin vials and cartridges. This collaboration is part of the Lilly 30x30 initiative, which aims to improve access to quality health care for 30 million people living in resource-limited settings annually by 2030. https://www.prnewswire.com/news-releases/lilly-and-eva-pharma-announce-regulatory-approval-and-release-of-locally-manufactured-insulin-in-egypt-302333269.html XX Can we add treating sleep apnea to the list of applications for terzepatide? That’s the generic for Zepbound and Mounjaro. Phase 3 study shows that 10- and 15-milligram injections of Zepbound "significantly reduced the apnea-hypopnea index" among those who have obesity and moderate-to-severe obstructive sleep apnea. Eli Lilly said there was nearly a 20% reduction in weight among those in the trials. The company said it plans to submit its findings to the Food and Drug Administration and other global regulatory agencies beginning mid-year. https://www.aol.com/popular-weight-loss-drug-could-131507702.html XX Health Canada okays Tandem’s tslim X2 with Dexcom G7 and G6 making it the first and only insulin pump in Canada that is integrated with both Dexcom sensors. Now, t:slim X2 users in Canada can experience even more choice when it comes to CGM compatibility, along with the option to spend more time in closed loop with Dexcom G7’s 30-minute sensor warm-up time, faster than any other CGM on the market.3 In addition, t:slim X2 users who pair Dexcom G7 with an Apple smartwatch4 can see their glucose numbers directly from their watch without having to access their pump or smartphone4. Tandem will email all in-warranty t:slim X2 users in Canada with instructions on how to add the new compatibility feature free of charge via remote software update. t:slim X2 pumps pre-loaded with the updated software will begin shipping to new customers in early January 2025. To check coverage and start the process of getting a Tandem insulin pump, please visit tandemdiabetes.ca. https://www.businesswire.com/news/home/20241210731189/en/Tandem-tslim-X2-Insulin-Pump-Now-Compatible-with-Dexcom-G7-CGM-in-Canada XX A federal jury on Tuesday awarded Insulet $452 million in its patent skirmish with EOFlow over insulin patch pumps. The jury awarded Insulet $170 million in compensatory damages from EOFlow and an additional $282 million in exemplary damages for willful and malicious misappropriation. A judge has not yet entered a judgment on the decision. Insulet filed a lawsuit in the U.S. District Court for the District of Massachusetts in 2023, claiming EOFlow copied patented components of its Omnipod insulin pumps. In October 2023, the Massachusetts district court issued a preliminary injunction against EOFlow. Following that decision, Medtronic called off plans to buy EOFlow for about $738 million. A federal appeals court later overturned the preliminary injunction, and EOFlow resumed selling its devices in Europe. The company recently defended against a separate injunction filed by Insulet in Europe’s Unified Patent Court, according to Korea Biomedical Review, an online English newspaper based in Seoul, South Korea. The Massachusetts jury found this week that EOFlow and CEO Jesse Kim, as well as two of three former Insulet employees who were named as defendants in the lawsuit, misappropriated Insulet’s trade secrets. Insulet CEO Jim Hollingshead said the company is “extremely pleased with the jury’s verdict.” EOFlow did not immediately respond to a request for comment. https://www.medtechdive.com/news/insulet-eoflow-jury-verdict-patent-lawsuit/734745/ XX A tele-education program for health care providers who treat people with diabetes resulted in significant improvements in patient outcomes, including better blood sugar levels and increased use of medical devices to manage the disease, a University of Florida study finds. Led by researchers in the UF College of Public Health and Health Professions and the UF College of Medicine, the program used the Extension for Community Health Care Outcomes model, which has been adopted worldwide to train clinicians who treat patients with a variety of conditions. Known as Project ECHO, this is one of the first to demonstrate patient benefits for the program in a large, randomized trial. The findings appear in the journal Diabetes Care. https://ufhealth.org/news/2024/clinician-training-program-leads-to-better-outcomes-for-patients-with-diabetes XX New app under development to make driving safer for people with diabetes. Diabetes Driving Pal says it will use CGM data and guide you while you are driving without any annoying alerts. Guidance/suggestions will be on your car dashboard so that you don't have to look at phone and it will be very individualized and actionable. In a study last year, ~70% of people have reported (5% reported accident) to have at least one low blood sugar while driving and most reported that CGM alerts were not enough to protect them. We are hoping to start beta testing in a few months. We are trying to raise the fund to develop this product. We need your support. For more information, please visit: https://lnkd.in/gTDhnDc4 XX I’m also going to link to the top ten most read diabetes and endocrinology stories of 2024 from Medscape. This is almost all GLP-1 related.. and mostly for people with type 2. https://www.medscape.com/viewarticle/icymi-top-10-diabetes-endocrinology-stories-2024-2024a1000n6u?&icd=login_success_email_match_fpf XX That’s it for the last In the News of 2024! Don’t miss out episode next week with a look ahead to what we’re watching in 2025. I’m SS I’ll see you back here soon……
D
Diabetes Connections | Type 1 Diabetes
1 Sernova’s Cell Pouch System - An Update on the Path to Insulin Independence 31:20
31:20
나중에 재생
나중에 재생
리스트
좋아요
좋아요
31:20A few weeks ago, Sernova they announced their cell pouch system of islet cell transplants has seen seven people achieve insulin independence and has kept one person off of insulin injections for four years. What does that really mean going forward? I’m talking to their new CEO Jonathan Rigby and to Frank Shannon, Senior Vice President, Clinical Development and Regulatory Affairs More about Sernova here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.…
D
Diabetes Connections | Type 1 Diabetes
1 “The Cost of Not Knowing” - What people with T1D say about screening 27:34
27:34
나중에 재생
나중에 재생
리스트
좋아요
좋아요
27:34The concept and practice of screening for type 1 diabetes has changed significantly in the last decade. It used to be something you might have heard about at diabetes camp or a conference and weren’t quite sure what to do with the information. But now, you can get actionable results with the approval of Tzield and potential development of other prevention treatments. But what do people with diabetes actually think about screening? Beyond Type 1 asked.. you answered.. and we’re talking about it. Full info on the screening survey here This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.…
D
Diabetes Connections | Type 1 Diabetes
1 In the News.. Defining T1D stages, InsuJet approval, T2D dementia risk and more! 6:31
6:31
나중에 재생
나중에 재생
리스트
좋아요
좋아요
6:31It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: A push to change the defined stages of T1D, InsuJet is approved in Canada, new study linked T2D and dementia, new drug looked at to prevent hypoglycemia, big honors for a T1D author and more! Our interview with Clare Edge here. Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX The understanding of type 1 has changed a lot in the last 10-15 years, specifically with the definition of stages of the disease. Now some researchers suggest the current 2015 model is ready for another update. University of Florida Health diabetes researchers and collaborators last week issued a call to action in The Lancet Diabetes & Endocrinology, urging the development of a more precise method of calculating type 1 diabetes risk. Under the current staging system, this is Stage 1 of the disease, when a patient does not yet have elevated blood sugar but has two or more of these autoantibodies in the blood. Stage 2 is diagnosed when blood sugar begins to rise, indicating a dysfunctional pancreas in a patient who does not yet have clinical type 1 diabetes. That comes in Stage 3 with high blood sugar and, eventually, the classic symptoms of the disease, including frequent urination, weight loss and fatigue. Jacobsen, however, said the staging system requires more precision. This is especially important as the current staging model determines if a patient is eligible to receive a drug therapy called teplizumab, the only Food and Drug Administration-approved medication that can delay the onset of type 1 diabetes by an average of two years. The staging system, however, does not include a patient’s age and these researchers say additional markers that would be important to consider include a greater array of abnormal metabolic measures beyond blood sugar and the presence of more autoantibodies. https://www.gainesville.com/story/news/healthcare/2024/12/04/uf-health-scientists-propose-update-to-type-1-diabetes-staging-system/76734459007/ XX A product called InsuJet gets approval in Canada. Made by NuGen Medical Devices, InsuJet™ is a needle-free injection system. It’s already approved for sale in 42 countries – not yet the US. Their website says InsuJet’s jet-injected fluid penetrates the skin through a small orifice of a special nozzle, creating a thin, high pressure stream. This way, insulin doesn’t remain around the place of injection, like it does with a needle. Instead, with InsuJet, the insulin is deposited into the subcutaneous tissue where it’s easily absorbed and acts faster– saving you money, time, and discomfort. https://finance.yahoo.com/news/nugen-announces-canada-wide-launch-221500674.html XX Individuals diagnosed with type 2 diabetes before the age of 50 may be at a higher risk of developing dementia later in life. A study led by researchers at NYU Rory Meyers College of Nursing, says the risk is notably greater among adults with obesity. Type 2 diabetes is a known risk factor for dementia. Although the underlying mechanisms are not fully understood, scientists think that some of the hallmarks of diabetes—such as high blood sugar, insulin resistance, and inflammation—may encourage the development of dementia in the brain. The researchers note that this greater understanding of the connection between diabetes onset, obesity, and dementia may help inform targeted interventions to prevent dementia. https://scitechdaily.com/diagnosed-young-with-diabetes-your-dementia-risk-may-be-higher/ XX Embecta is out of the insulin patch pump business – just months after getting the ok from the FDA. Embecta received FDA clearance for its insulin patch pump in September. The device is indicated for people with Type 1 or Type 2 diabetes and includes a 300-unit insulin reservoir to support people with higher daily insulin needs. However, the version Embecta received clearance for was an open-loop patch pump, where users manually control insulin delivery, while the firm’s goal was to develop a closed-loop version, which automatically delivers insulin when needed. The CEO also expects competition in closed-loop devices for people with Type 2 diabetes to intensify, with Insulet receiving FDA clearance for its Omnipod 5 patch pump for Type 2 diabetes in August. https://www.medtechdive.com/news/embecta-discontinue-patch-pump/734059/ XX Sanofi invests in a company developing a new drug to prevent hypoglycemia. We reported on Zucara Therapeutics back in 2022 and they’ve been moving ahead with ZT-01. ZT-01 is a medication being developed to help prevent dangerous low blood sugar (hypoglycemia) by fixing how the body normally fights it. In people without diabetes, a hormone called glucagon is released to raise blood sugar when it gets too low. But in people with insulin-dependent diabetes, like type 1 diabetes or some forms of type 2 diabetes, this process doesn’t work well because another hormone, somatostatin (SST), blocks glucagon from being released. ZT-01 works by blocking the effects of somatostatin, allowing the body to release more glucagon when it’s needed. This could help people with diabetes avoid severe low blood sugar episodes. https://www.prnewswire.com/news-releases/zucara-therapeutics-announces-strategic-investment-from-sanofi-as-part-of-us20-million-series-b-financing-302301820.html XX Omnipod 5 is now compatible with the FreeStyle Libre 2 plus. The company says the recent development “ makes Omnipod 5 the most connected tubeless AID system in the U.S.” It’s already compatible with Dexcom’s G6 and G7 CGMs. https://www.businesswire.com/news/home/20241120268759/en/Insulet-Announces-Omnipod%C2%AE-5-System-is-Now-Compatible-with-Abbott%E2%80%99s-FreeStyle-Libre-2-Plus-Sensor-in-the-U.S. XX A new study involving 11 clinical centers across the United States aims to uncover how type 1 diabetes (T1D) impacts brain health and cognitive function in children. Led by the Keck School of Medicine of the University of Southern California, this is a five-year study to explore critical questions about how environmental, lifestyle, social and clinical factors affect brain development during childhood — a period crucial for cognitive growth. https://www.managedhealthcareexecutive.com/view/new-study-to-explore-impact-of-type-1-diabetes-on-children-s-brain-development XX Dexcom looking to partner with smart ring company Oura. Originally launched to track sleep patterns, the latest Oura technology collects more than 20 biometrics ranging from heart rate and activity metrics to sleep and body temperature monitoring. The companies say the new partnership is intended to provide users with seamless integration between the two ecosystems so shared users can track their glucose levels and understand the impact of behaviors and biology on their metabolic health. https://www.forbes.com/sites/saibala/2024/11/29/smart-ring-maker-oura-hits-5-billion-in-valuation--strikes-major-partnership-with-dexcom/ XX WEDNESDAY, Dec. 4, 2024 (HealthDay News) -- Taking even high doses of supplementary vitamin D won't lower an older person's odds for type 2 diabetes , new research confirms. They published their findings Dec. 2 in the journal Diabetologia . The new research followed on data from other studies that had suggested that people with especially low levels of vitamin D might face a higher risk for diabetes. That was true for people who were already prediabetic, especially. To find out, researchers led by Jirki Vyrtanen , from the University of Eastern Finland, randomly assigned nearly 2,300 people aged 60 or older to receive either placebo pills or 40 or 80 micrograms of vitamin D3 supplements per day, for five years. At the end of the five years, "105 participants developed type 2 diabetes: 38 in the placebo group, 31 in the group receiving 40 micrograms of vitamin D3 per day, and 36 in the group receiving 80 micrograms of vitamin D3 per day," according to a university news release. In other words, there were no significant differences in the rate at which people developed type 2 diabetes, regardless of how much supplemental vitamin D they took. Vytanen's team also saw no benefit from high-dose supplements on a person's blood sugar or insulin levels, or measures of overweight/obesity. The bottom line, according to the researchers: For any healthy, non-prediabetic person with healthy vitamin D levels, upping intake of the vitamin won't alter your odds for diabetes or its common risk factors. https://www.usnews.com/news/health-news/articles/2024-12-04/high-dose-vitamin-d-supplements-wont-prevent-diabetes-in-healthy-seniors XX Big congrats to author Clare Edge – recent guest on the podcast. Her book, Accidental Demons is featured on People Magazine’s top ten book gift suggestions for this year! Whether you’re looking for books about winter and the holidays, a primer on some of this year’s buzziest musicians and characters or that "one more chapter" kind of bedtime favorite, there’s sure to be a book out there to suit their taste. Bernadette Crowley, also known as Ber, comes from a long line of witches. When Ber is diagnosed with diabetes, however, she learns that every time she tests her blood sugar, demons accidentally slip into the human dimension — and it’s up to Ber and her sister, Maeve, to stop them. This fantastical book is a great escape for young readers over holiday break. Buy Now Top ten books https://people.com/kids-gift-book-suggestions-wicked-taylor-swift-books-8752097…
D
Diabetes Connections | Type 1 Diabetes
This week, the question “What should the healthcare system for people with T1D look like? Led to something completely unique. It sounds too good to be true but Blue Circle Health is providing FREE care for people with type 1 diabetes. When I heard that, I knew I had to check it out. I’m talking to CEO Len D'Avolio about their recent expansion – Blue Circle Health is now in five states and plans to add more – what their goals are, and who’s actually paying for this. Learn more about Blue Circle Health This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Previous holiday episodes here Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.…
D
Diabetes Connections | Type 1 Diabetes
1 T1D Tech Gift Guide: Must-Haves for the Holidays with Diabetech 43:29
43:29
나중에 재생
나중에 재생
리스트
좋아요
좋아요
43:29This week, we know you’re gearing up for holiday shopping and watching those Black Friday specials, so we’re making a list of diabetes tech that should be on your list! I’m chatting with Justin from Diabetech about devices and apps that don’t make diabetes easy but can lighten the load a bit. Some of these are even a little but fun. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Join us at an upcoming Moms' Night Out event! Previous holiday episodes here We work with some of the companies/products featured in this episode. Listed here for full disclosure and so you can find what you might be looking for! Sweet Dreams Justin has worked on sponsored content Sugar Pixel Justin's affiliate link: https://bit.ly/SugarPixel Frio Get 10% off with code JUSTIN10 - Use link: https://bit.ly/FRIO Frio has been a sponsor of Moms' Night Out Skin Grip Get 10% off with code JUSTIN10 - Use link: https://bit.ly/SkinGripJustin Skin Grip has been a sponsor of Moms' Night Out Tempramed Tempramed has been a sponsor of Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.…
D
Diabetes Connections | Type 1 Diabetes
1 Overnight Automation for Insulin Pen Users? CEO John Sjölund explains Luna Diabetes 34:04
34:04
나중에 재생
나중에 재생
리스트
좋아요
좋아요
34:04Luna Diabetes is moving ahead with something completely new – automated dosing overnight for insulin pen users. This is an add-on therapy – a tiny pump designed for use only during sleep, you keep using injections during the day. Sounds like extra work and extra gear, but the people behind Luna say the benefits speak for themselves and that the idea is extremely well received. They’ve just moved into clinical trials and asking CEO John Sjolund to explain it all. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn more about Luna Check out the clinical trials for Luna (more locations may be added) Join us at an upcoming Moms' Night Out event! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.…
D
Diabetes Connections | Type 1 Diabetes
1 In the News... World Diabetes Day, Free T1D Care(?!), More Mounjaro info, New pump system, and more! 7:17
7:17
나중에 재생
나중에 재생
리스트
좋아요
좋아요
7:17It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: World Diabetes Day roundup, existing drugs examined for T1D prevention, Blue Circle Health expands its novel T1D care model, Mounjaro studied further, Canada approves a new pumps system, and tragedy in the diabetes community. Find out more about Moms' Night Out Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Learn more about AG1 from Athletic Greens Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links: Hello and welcome to Diabetes Connections In the News! I’m Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. XX Of course, World Diabetes Day was yesterday. November 14 marks the birthday of Sir Frederick Banting. who discovered insulin along with Charles Best in 1922. Lots of the tech companies are taking action.. I’m going to link up a great article highlighting what many of them are doing…. from Medtronics Blue Balloon challenge to Dexcom’s Nick Jonas video and a lot more. https://www.drugdeliverybusiness.com/world-diabetes-day-2024/ XX A new triple combo therapy could restore insulin production in people with type 1 using existing medications. Levicure’s triple-combo oral therapy is already considered very safe, because it involves two drugs approved by the U.S. Food and Drug Administration (FDA) and a well-known supplement. The therapy is a combination of: DPP4-inhibitors, a common type 2 diabetes medication Proton pump inhibitors (PPIs), a drug for severe acid reflux A proprietary version of gamma-aminobutyric acid (GABA), a supplement often used to treat anxiety Levicure says the combined effect can block beta cell destruction, suppress autoimmunity, and restore beta cell function. So far, Levicure’s triple therapy has gone through only one retrospective chart review; it has not been put to the test in a randomized controlled trial https://www.diabetesdaily.com/blog/can-this-triple-combo-oral-therapy-restore-insulin-production-733261/ XX Blue Circle Health is expanding it’s unique approach to type 1 care. Already active in Florida, Maine & Vermont, it will now be in Delaware and Ohio. Blue Circle Health is free and develops a personalized care plan for each participant, tailored to their unique needs, and offers comprehensive multidisciplinary support over a six-month period. It’s paid for by the Helmsley Charitable Trust. The program is available to people 18 years of age and older that speak Spanish or English, regardless of insurance coverage or citizen status. We’ve got an upcoming podcast episode all about Blue Circle coming up soon. https://www.prnewswire.com/news-releases/blue-circle-health-expands-to-delaware-and-ohio-to-address-health-system-barriers-to-type-1-diabetes-care-and-education-302304170.html XX An international team of experts has created the world's first evidence-based guide for eating lower and low carb. The group says until now, people with type 1 diabetes and their healthcare providers have lacked comprehensive resources to help implement this approach safely and effectively. The guide provides essential information for dietitians and nutritionists and empowers them to work collaboratively with individuals and families who are interested in reducing carbohydrates. It’s free and we’ve got the download link in the show notes. https://www.newswire.ca/news-releases/international-team-launches-first-guide-for-carbohydrate-reduction-in-type-1-diabetes-883729104.html XX A new pump system is available in Canada. mylife YpsoPump insulin pump and CamAPS FX hybrid closed-loop algorithm by Health Canada. mylife Loop consists of the mylife YpsoPump, a lightweight intuitive insulin pump, integrated with the CamAPS FX hybrid closed-loop, a mobile phone-based algorithm, and the Dexcom G6 Continuous Glucose Monitoring (CGM) System. Working together, these components provide an innovative, automated insulin delivery (AID) system designed to simplify insulin therapy and improve glycemic control for Canadians living with diabetes. "The approval of the mylife YpsoPump and CamAPS FX marks an important milestone as we bring these advanced technologies to the Canadian market," said Sébastien Delarive, Chief Business Officer of Ypsomed Diabetes Care. "Although Ypsomed is relatively new in Canada, our established leadership in diabetes care throughout Europe provides a solid foundation for delivering innovative solutions to Canadians living with type 1 diabetes." "We are excited to see both mylife YpsoPump and CamAPS FX approved," said Karina Schneider, General Manager at Ypsomed Canada. "This step brings us closer to offering an integrated solution that will help simplify diabetes management for Canadian patients, empowering them to take more control of their health." https://finance.yahoo.com/news/ypsomed-camdiab-receive-health-canada-205500840.html XX The FDA updates the labels for all GLP-1 receptor agonists with a warning about pulmonary aspiration during general anesthesia or deep sedation. The affected drugs are semaglutide (Ozempic, Rybelsus, Wegovy); liraglutide (Saxenda, Victoza); and the dual glucose-dependent insulinotropic polypeptide (GIP)/GLP-1 tirzepatide (Mounjaro, Zepbound). the Medication Guide section of the label also has new additions. Patients are counseled to tell their healthcare provider if they are scheduled to have surgery or other procedures that use anesthesia or deep sleepiness (deep sedation). They are alerted that the GLP-1 RAs they are taking may cause serious side effects, including food or liquid getting into the lungs during surgery or other procedures that use anesthesia or deep sedation. Patients are advised to tell all their healthcare providers that they are taking a GLP-1 RA before they are scheduled to have surgery or other procedures. https://www.medscape.com/viewarticle/fda-updates-glp-1-label-pulmonary-aspiration-warning-2024a1000k84?form=fpf XX Following an impressive data drop this summer highlighting the potential for Eli Lilly’s tirzepatide to stave off progression to Type 2 diabetes in prediabetic patients, the Indianapolis-based drugmaker is laying out full results from its longest completed study of the dual GIP/GLP-1 receptor agonist to date. In the three-year SURMOUNT-1 trial, tirzepatide curbed the risk of disease progression to Type 2 diabetes by 94% versus placebo in adult prediabetes patients who were obese or overweight, Lilly said in a release Wednesday. The number represents a pooled result from three tirzepatide doses (5 mg, 10 mg and 15 mg) studied in the trial. Putting those results into perspective, one new case of diabetes could be prevented for every nine patients treated with tirzepatide, which is marketed in the U.S. as Mounjaro for Type 2 diabetes and as Zepbound for obesity, Lilly said. https://www.fiercepharma.com/pharma/lilly-unwraps-detailed-data-showing-tirzepatide-kept-nearly-99-pre-diabetic-patients XX Edgparke commeical? XX https://www.bloomberg.com/news/articles/2024-10-25/apple-secretly-tests-blood-sugar-app-in-sign-of-health-ambitions XX XX And finally, many of you have likely already heard but we had some incredibly tragic news in the diabetes community, especially for the Breakthrough T1D ride community. I’m going to read from the Breakthrough T1D website: The leadership, staff, and volunteers of Breakthrough T1D mourn the tragic, sudden loss of five T1D Champions on Friday, Nov. 1, 2024. Jeff and Michelle Bauer, Josh and Tammy Stahl and Barry Sievers were all killed in a singe car crash. The group included two married couples and one single individual—all very close friends and veteran Breakthrough T1D Ride participants. Of this incredibly impactful group, I knew Michelle Bauer personally, I met her as Michelle Alswager – you may know her as Jesse’s mom. Her son, Jesse died from complications of type 1 in 2010. And that year, mile 23 on the JDRF ride was created as a mile of silence in memory of Jesse. Now all riders are asked to ride in silence for that mile not only in memory of Jesse, but all those lost to type 1 diabetes. Michelle wrote her book, Jesse Was Here and created a program that’s part of Beyond Type 1 to this day, all to help other families going through grief. She called me a few years ago when she was thinking of writing her book and I’m so grateful for our conversations and that our conversations may have helped her get it out there into a world where it’s so needed. But we need Michelle here to talk about grief. More about talking to Michelle about the book). Please, write the book, ride the bike, do the ironman, follow your heart and your dreams. All of these incredible people gone too soon. https://www.breakthrought1d.org/news-and-updates/breakthrough-t1d-mourns-tragic-sudden-loss-of-five-ride-champions/ Thanks for joining me..…
D
Diabetes Connections | Type 1 Diabetes
1 This period pad measures A1C - All about Qvin with CEO Dr. Sara Naseri 33:06
33:06
나중에 재생
나중에 재생
리스트
좋아요
좋아요
33:06Qvin is a small company intent on prioritizing women’s health. And they’re doing it in a way no one has thought to do before. They got FDA clearance to measure A1c with their patented period pads. Qvin is the first and only FDA-cleared menstrual pad scientifically proven to collect blood for lab testing. Featured in Time Magazine’s best inventions of 2024, CEO Dr. Sara Naseri tells me this is just the start of what they want to do for women’s health autonomy. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn more about Qvin Join us at an upcoming Moms' Night Out event! Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.…
D
Diabetes Connections | Type 1 Diabetes
1 One of only three NBA players EVER with T1D, Gary Forbes now inspires off the court 42:14
42:14
나중에 재생
나중에 재생
리스트
좋아요
좋아요
42:14Living with type 1 diabetes as a professional athlete is an exercise in intense management and mental stamina. Gary Forbes did it before today’s technology – no CGMs or AID pumps, not even fast acting insulin at the start of his career! – and without a diabetes community. He’s making up for lost time with that last bit.. connecting in a way that he says has changed how he looks at T1D. Of course, we’re talking about basketball – as one of only three NBA players with type 1, Gary has a very unique perspective and a great message he’s getting out in a new comic series. This podcast is not intended as medical advice. If you have those kinds of questions, please contact your health care provider. Learn more about Gary's comics: Sole Survivors Learn more about Diabetes Legends and Rob Howe's other projects Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom Edgepark Medical Supplies Check out VIVI Cap to protect your insulin from extreme temperatures Drive research that matters through the T1D Exchange The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com Reach out with questions or comments: info@diabetes-connections.…
플레이어 FM에 오신것을 환영합니다!
플레이어 FM은 웹에서 고품질 팟캐스트를 검색하여 지금 바로 즐길 수 있도록 합니다. 최고의 팟캐스트 앱이며 Android, iPhone 및 웹에서도 작동합니다. 장치 간 구독 동기화를 위해 가입하세요.